News | August 16, 2022
NGL Fine-Chem planning greenfield expansion at Tarapur
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Investment in response to increased demand for North American-based chemistry services
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal
EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%
He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years
Subscribe To Our Newsletter & Stay Updated
